RPRX: Royalty Pharma plc - Class A Company Profile & Statistics

About

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.

Info & Links

CEO

Pablo Legorreta

Headquarters

110 East 59th Street
New York, NY 10022, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Royalty Pharma plc - Class A Statistics

Valuation Measures

Market Capitalization²

15.57B

Enterprise Value

22.23B

Enterprise Value/EBITDA(ttm)

14.22

Price to Earnings Ratio(ttm)

5.88

Price to Sales(ttm)

6.31

Price to Book(mrq)

1.40

Price to Cash(ytd)

5.32

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

108.65%

Profit Margin(ttm)

49.77%

Return on Equity(ttm)

24.65%

Return on Invested Capital(ttm)

10.30%

Return on Assets(ttm)

14.44%

Income Statement

Revenue(ttm)

2.27B

Revenue Per Share(ttm)

3.85

Gross Profit(ttm)

2.27B

EBITDA(ttm)³

1.56B

Net Income Available to Common(ttm)

1.15B

Diluted EPS(ttm)

1.93

Share Statistics

Beta (5Y Monthly)

0.46

52-Week Change

-9.20%

S&P 500 52-Week Change

24.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

589.18M

Dividend Yield

3.46%

Float⁴

477.83M

% Held by Insiders

18.90%

% Held by Institutions

54.35%

Balance Sheet

Total Cash(mrq)

998.55M

Total Cash Per Share(mrq)

1.69

Total Debt(mrq)

7.61B

Total Debt/Equity(mrq)

74.16%

Current Ratio(mrq)

1.54%

Quick Ratio(mrq)

1.54%

Book Value Per Share(mrq)

10.45

Cash Flow

Operating Cash Flow Per Share(ytd)

3.42

Free Cash Flow(ytd)

17.18M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

RPRX

Royalty Pharma plc - Class A

Royalty Pharma plc - Class A Profile